🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Platinum Doublet

Found 309 matching trials

STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1

PHASE2

To learn if the drug combination of tiragolumab and ivonescimab can help to...

Status

Withdrawn

Location

Multiple Locations

Start Date

2025-07-28

Trial ID

NCT07038915

Treatments Being Tested

Tiragolumab Ivonescimab

ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs

PHASE2

The goal of this prospective study is to explore the safety and preliminary...

Status

Recruiting

Location

Fudan University Shanghai Cancer Center

Start Date

2025-01-15

Trial ID

NCT06775743

Treatments Being Tested

ORIENT-31 regimen SBRT

Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC

PHASE2

To explore the efficacy and safety of vebreltinib plus platinum-doublet che...

Status

Not Yet Recruiting

Location

241 West Huaihai Road, Xuhui District, Shanghai, 200030, China.

Start Date

2026-03-30

Trial ID

NCT07549061

Treatments Being Tested

Vebreltinib Chemotherapy

Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer

PHASE1

The purpose of this study is to determine if the use of exploratory immunol...

Status

Completed

Location

Memorial Sloan Kettering Cancer Center at Basking Ridge

Start Date

2013-07-05

Trial ID

NCT01899989

Treatments Being Tested

Stereotactic Body Radiation Therapy (SBRT)cisplatin or carboplatin-based

De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction

PHASE2

Immunotherapeutic approaches recently have demonstrated clinical efficacy i...

Status

Recruiting

Location

Aix-en-Provence - CH

Start Date

2022-05-02

Trial ID

NCT05255302

Treatments Being Tested

Pembrolizumab before randomization Chemotherapy Pemetrexed Pembrolizumab after randomization

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

PHASE3

Aumolertinib is a third-generation epidermal growth factor receptor (EGFR) ...

Status

Terminated

Location

Highlands Oncology Group

Start Date

2022-12-14

Trial ID

NCT05493501

Treatments Being Tested

Aumolertinib monotherapy Osimertinib monotherapy Pemetrexed Cisplatin Carboplatin Paclitaxel Nab paclitaxel Gemcitabine

VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer

PHASE1

This is a nonrandomized, open phase I dose escalation and extension clinica...

Status

Unknown

Location

Zhangli

Start Date

2022-09-21

Trial ID

NCT05489731

Treatments Being Tested

VIC-1911 Osimertinib Mesylate Tablets

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

This ALCHEMIST trial studies genetic testing in screening patients with sta...

Status

Active Not Recruiting

Location

University of Alabama at Birmingham Cancer Center

Start Date

2014-09-26

Trial ID

NCT02194738

Treatments Being Tested

Biospecimen Collection Carboplatin Cisplatin Clinical Observation Computed Tomography Crizotinib Cytology Specimen Collection Procedure Echocardiography Test Erlotinib Gemcitabine Hydrochloride Nivolumab Paclitaxel Pembrolizumab Pemetrexed Pemetrexed Disodium Placebo Administration Positron Emission Tomography

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

PHASE3

The purpose of this study is to evaluate sacituzumab tirumotecan versus pem...

Status

Active Not Recruiting

Location

Kaiser Permanente - Oakland ( Site 0054)

Start Date

2024-06-11

Trial ID

NCT06305754

Treatments Being Tested

Sacituzumab tirumotecan Pemetrexed Carboplatin H1 Receptor Antagonist H2 Receptor Antagonist Acetaminophen (or equivalent)Dexamethasone (or equivalent)Steroid Mouthwash (dexamethasone or equivalent)

Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC

PHASE1

Chemotherapeutic agents exert significant immunomodulatory effects by influ...

Status

Recruiting

Location

the First Affiliated Hospital of Zhengzhou University

Start Date

2025-06-01

Trial ID

NCT06896422

Treatments Being Tested

Glutathione PD1 Inhibitor Chemotherapy

Previous Next